{"title":"Impact of location and size of minimal extrathyroidal extension on lymph node metastasis in papillary thyroid cancer: a retrospective analysis.","authors":"Hongliang Zhan, Yiyan Hong, Longying Zhang, Kunzhai Huang, Miaomiao Zheng, Fuxing Zhang","doi":"10.21037/gs-24-273","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 8th edition of the American Joint Committee on Cancer (AJCC)'s T-stage for differentiated thyroid cancer (DTC) removes minimal extrathyroidal extension (mETE), while ignoring the risk of mETE would lead to overtreatment or inadequate treatment. The aim of this study was to investigate the impact of location and size of mETE on lymph node metastasis in papillary thyroid cancer (PTC).</p><p><strong>Methods: </strong>A retrospective analysis of 267 patients who underwent unilateral radical surgery for PTC was conducted. According to the postoperative pathology, they were divided into mETE group (121 patients) and non-mETE group (146 patients). The number of lymph nodes dissected and the number of lymph nodes metastasized were compared between the two groups. The linear regression analysis and the receiver operating characteristic (ROC) curves were performed to evaluate the impact of the locations and sizes on lymph node metastasis.</p><p><strong>Results: </strong>There was no significant difference in the number of lymph node dissected between the mETE group and the non-mETE group. The tumor located at the upper part and the size <1.0 cm in mETE group showed a higher number of lymph node metastasis (0.78±0.88 <i>vs.</i> 0.25±0.45, P=0.03). Meanwhile, in the mETE group, the number of patients with lymph node metastasis was higher than that in the non-mETE group. Further subgroup analysis revealed that for PTC patients with tumors at the upper part and size <1.0 cm, the number of those with lymph node metastasis in the mETE group was also greater than that in the non-mETE group. Furthermore, the Spearman correlation analysis showed a positive correlation between tumors located at the upper part with a size <1.0 cm and lymph node metastasis rate (R=0.647, P=0.004). Additionally, if the upper part tumor was within 1 cm, the tumor's size was able to identify the lymph node metastasis, with the optimal cut-off point of 0.45 cm (Youden index =0.650).</p><p><strong>Conclusions: </strong>When tumors combine with mETE, the probability of lymph node metastasis increases in tumors located at the upper part with a size <1.0 cm. Especially, when the upper part tumor is within 1 cm, the tumors of size ≥0.45 cm are more likely to have lymph node metastasis.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480871/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gland surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/gs-24-273","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The 8th edition of the American Joint Committee on Cancer (AJCC)'s T-stage for differentiated thyroid cancer (DTC) removes minimal extrathyroidal extension (mETE), while ignoring the risk of mETE would lead to overtreatment or inadequate treatment. The aim of this study was to investigate the impact of location and size of mETE on lymph node metastasis in papillary thyroid cancer (PTC).
Methods: A retrospective analysis of 267 patients who underwent unilateral radical surgery for PTC was conducted. According to the postoperative pathology, they were divided into mETE group (121 patients) and non-mETE group (146 patients). The number of lymph nodes dissected and the number of lymph nodes metastasized were compared between the two groups. The linear regression analysis and the receiver operating characteristic (ROC) curves were performed to evaluate the impact of the locations and sizes on lymph node metastasis.
Results: There was no significant difference in the number of lymph node dissected between the mETE group and the non-mETE group. The tumor located at the upper part and the size <1.0 cm in mETE group showed a higher number of lymph node metastasis (0.78±0.88 vs. 0.25±0.45, P=0.03). Meanwhile, in the mETE group, the number of patients with lymph node metastasis was higher than that in the non-mETE group. Further subgroup analysis revealed that for PTC patients with tumors at the upper part and size <1.0 cm, the number of those with lymph node metastasis in the mETE group was also greater than that in the non-mETE group. Furthermore, the Spearman correlation analysis showed a positive correlation between tumors located at the upper part with a size <1.0 cm and lymph node metastasis rate (R=0.647, P=0.004). Additionally, if the upper part tumor was within 1 cm, the tumor's size was able to identify the lymph node metastasis, with the optimal cut-off point of 0.45 cm (Youden index =0.650).
Conclusions: When tumors combine with mETE, the probability of lymph node metastasis increases in tumors located at the upper part with a size <1.0 cm. Especially, when the upper part tumor is within 1 cm, the tumors of size ≥0.45 cm are more likely to have lymph node metastasis.
背景:美国癌症联合委员会(AJCC)第8版的分化型甲状腺癌(DTC)T分期删除了最小甲状腺外扩展(mETE),而忽视mETE的风险将导致过度治疗或治疗不当。本研究旨在探讨mETE的位置和大小对甲状腺乳头状癌(PTC)淋巴结转移的影响:方法:对267例接受单侧PTC根治术的患者进行回顾性分析。根据术后病理结果,将患者分为 mETE 组(121 例)和非 mETE 组(146 例)。比较了两组患者的淋巴结清扫数量和淋巴结转移数量。通过线性回归分析和接收者操作特征曲线(ROC)来评估位置和大小对淋巴结转移的影响:结果:mETE 组与非 mETE 组切除的淋巴结数量无明显差异。mETE组淋巴结清扫数量与非mETE组无明显差异(肿瘤位于上部、大小为0.25±0.45,P=0.03)。同时,在mETE组中,淋巴结转移的患者数量高于非mETE组。进一步的亚组分析表明,对于肿瘤位于上部且大小结论的 PTC 患者,mETE 组的淋巴结转移数量高于非 mETE 组:当肿瘤合并 mETE 时,位于肿瘤上部、大小为 0.5 mm×0.5 mm 的肿瘤发生淋巴结转移的概率会增加。
期刊介绍:
Gland Surgery (Gland Surg; GS, Print ISSN 2227-684X; Online ISSN 2227-8575) being indexed by PubMed/PubMed Central, is an open access, peer-review journal launched at May of 2012, published bio-monthly since February 2015.